Stock FRTX FRESH TRACKS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Fresh Tracks Therapeutics, Inc.

Equities

FRTX

US10802T2042

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 01:02:54 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.9101 USD -1.14% Intraday chart for Fresh Tracks Therapeutics, Inc. +1.09% +3.53%
Mar. 15 Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 11.72 41.77 26.33 4.52 5.251
Enterprise Value (EV) 1 0.138 12.16 -0.4804 -4.111 -5.617
P/E ratio -0.33 x -0.91 x -0.47 x -0.2 x -0.83 x
Yield - - - - -
Capitalization / Revenue 1.48 x 22.9 x 65.2 x 0.65 x 0.66 x
EV / Revenue 0.02 x 6.68 x -1.19 x -0.59 x -0.7 x
EV / EBITDA -0.01 x -0.58 x 0.01 x 0.19 x 0.89 x
EV / FCF -0.01 x -0.96 x 0.02 x 0.35 x 2.1 x
FCF Yield -17,656% -104% 4,877% 285% 47.6%
Price to Book 1.68 x 1.54 x 1.1 x 0.63 x 0.53 x
Nbr of stocks (in thousands) 174 1,189 2,557 3,013 5,973
Reference price 2 67.50 35.12 10.30 1.500 0.8791
Announcement Date 3/18/20 3/9/21 3/15/22 3/30/23 3/15/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 10.89 7.917 1.822 0.404 6.943 8.006
EBITDA 1 -8.405 -24.14 -20.97 -40.22 -21.5 -6.319
EBIT 1 -8.454 -24.17 -20.98 -40.24 -21.53 -6.36
Operating Margin -77.65% -305.32% -1,151.26% -9,961.39% -310.15% -79.44%
Earnings before Tax (EBT) 1 -9.236 -23.88 -20.91 -39.47 -21.1 -5.694
Net income 1 -9.236 -23.88 -20.91 -39.47 -21.1 -5.694
Net margin -84.83% -301.59% -1,147.8% -9,770.79% -303.93% -71.12%
EPS 2 -401.5 -202.5 -38.39 -22.12 -7.515 -1.056
Free Cash Flow 1 4.568 -24.36 -12.64 -23.43 -11.73 -2.671
FCF margin 41.95% -307.72% -693.52% -5,799.91% -168.88% -33.36%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/3/19 3/18/20 3/9/21 3/15/22 3/30/23 3/15/24
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3
Net sales 1 0.132 0.104 0.092 4.315 0.486
EBITDA - - - - -
EBIT 1 -13.36 -6.305 -9.407 -1.458 -6.076
Operating Margin -10,120.45% -6,062.5% -10,225% -33.79% -1,250.21%
Earnings before Tax (EBT) 1 -13.25 -6.067 -9.41 -1.147 -6.018
Net income 1 -13.25 -6.067 -9.41 -1.147 -6.018
Net margin -10,040.15% -5,833.65% -10,228.26% -26.58% -1,238.27%
EPS 2 -7.200 -2.700 -3.600 -0.4500 -2.070
Dividend per Share - - - - -
Announcement Date 11/9/21 3/15/22 5/12/22 8/11/22 11/10/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 3.43 11.6 29.6 26.8 8.63 10.9
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 4.57 -24.4 -12.6 -23.4 -11.7 -2.67
ROE (net income / shareholders' equity) 91.5% 866% -121% -152% -131% -66.5%
ROA (Net income/ Total Assets) -68.5% -112% -50.6% -79.4% -67.3% -36.4%
Assets 1 13.49 21.25 41.3 49.71 31.35 15.65
Book Value Per Share 2 -42.00 40.20 22.80 9.390 2.380 1.660
Cash Flow per Share 2 4.730 38.40 25.30 10.10 2.880 1.820
Capex 1 0.01 0.01 0.02 0.04 0.05 -
Capex / Sales 0.11% 0.09% 1.26% 8.91% 0.68% -
Announcement Date 9/3/19 3/18/20 3/9/21 3/15/22 3/30/23 3/15/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FRESH TRACKS THERAPEUTICS, INC. Stock Fresh Tracks Therapeutics, Inc.
+3.53% 5.44M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. FRTX Stock
  4. Financials Fresh Tracks Therapeutics, Inc.